248 related articles for article (PubMed ID: 37495480)
1. Hospitalizations Among Veterans Treated for Metastatic Prostate Cancer With Abiraterone or Enzalutamide.
Riekhof F; Yan Y; Bennett CL; Sanfilippo KM; Carson KR; Chang SH; Georgantopoulos P; Luo S; Govindan S; Cheranda N; Afzal A; Schoen MW
Clin Genitourin Cancer; 2024 Apr; 22(2):18-26.e3. PubMed ID: 37495480
[TBL] [Abstract][Full Text] [Related]
2. The rates of septicemia in older adults with prostate cancer treated with abiraterone or enzalutamide: A population-based study.
Nikita N; Gandhi K; Keith SW; Sharma S; Kelly WK; Lu-Yao G
J Geriatr Oncol; 2024 Jun; 15(5):101773. PubMed ID: 38703693
[TBL] [Abstract][Full Text] [Related]
3. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
4. Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer.
Deol ES; Sanfilippo KM; Luo S; Fiala MA; Wildes T; Mian H; Schoen MW
J Geriatr Oncol; 2023 Jun; 14(5):101520. PubMed ID: 37263065
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS).
Liu Y; Zhang HM; Jiang Y; Wen Z; Bao EH; Huang J; Wang CJ; Chen CX; Wang JH; Yang XS
Clin Genitourin Cancer; 2023 Oct; 21(5):594-601.e2. PubMed ID: 37482524
[TBL] [Abstract][Full Text] [Related]
6. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
7. Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Schultz NM; Flanders SC; Wilson S; Brown BA; Song Y; Yang H; Lechpammer S; Kassabian V
Adv Ther; 2018 Oct; 35(10):1639-1655. PubMed ID: 30191463
[TBL] [Abstract][Full Text] [Related]
8. A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide.
Leuva H; Sigel K; Zhou M; Wilkerson J; Aggen DH; Park YA; Anderson CB; Hsu TM; Langhoff E; McWilliams G; Drake CG; Simon R; Bates SE; Fojo T
Semin Oncol; 2019; 46(4-5):351-361. PubMed ID: 31757478
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients.
Scailteux LM; Despas F; Balusson F; Campillo-Gimenez B; Mathieu R; Vincendeau S; Happe A; Nowak E; Kerbrat S; Oger E
Br J Clin Pharmacol; 2022 Jan; 88(1):336-346. PubMed ID: 34224605
[TBL] [Abstract][Full Text] [Related]
10. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
[TBL] [Abstract][Full Text] [Related]
11. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy.
Pilon D; Behl AS; Ellis LA; Robitaille MN; Lefebvre P; Dawson NA
Am Health Drug Benefits; 2017 May; 10(3):143-153. PubMed ID: 28626511
[TBL] [Abstract][Full Text] [Related]
14. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
15. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ; Annala M; Taavitsainen S; Finch DL; Oja C; Vergidis J; Zulfiqar M; Sunderland K; Azad AA; Kollmannsberger CK; Eigl BJ; Noonan K; Wadhwa D; Attwell A; Keith B; Ellard SL; Le L; Gleave ME; Wyatt AW; Chi KN
Lancet Oncol; 2019 Dec; 20(12):1730-1739. PubMed ID: 31727538
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer.
Yamada S; Shiota M; Blas L; Matsumoto T; Kashiwagi E; Takeuchi A; Inokuchi J; Shiga KI; Yokomizo A; Eto M
Prostate Int; 2022 Mar; 10(1):50-55. PubMed ID: 35510101
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan.
Li PY; Lu YH; Chen CY
Front Oncol; 2022; 12():822375. PubMed ID: 35330713
[TBL] [Abstract][Full Text] [Related]
19. Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI.
Watson AS; Gagnon R; Batuyong E; Alimohamed N; Lee-Ying R
Clin Genitourin Cancer; 2022 Oct; 20(5):496.e1-496.e9. PubMed ID: 35599196
[TBL] [Abstract][Full Text] [Related]
20. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
